Seattle Genetics to acquire Cascadian Therapeutics for $614M to further bolster its cancer fight Seattle Genetics, a biotechnology company that develops antibody-based cancer treatments, announced Wednesday that it will acquire Cascadian Therapeutics and the… Read More
